RxDoctor Payments Data

Jenny Wong, MD

Family Medicine · Coronado, CANPI 1689837742

Payments from drug & device makers

$2,483in general payments, 2019–2025

Across 119 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$373
  • Lilly USA, LLC$315
  • Eisai Inc.$265
  • AstraZeneca$246
  • AbbVie$234
  • Pfizer$204
  • plus $846 from 18 others

What the payments were for

  • Food & beverage$2,483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,483 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$64,137
Medicare patients
174
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$42,388
RybelsusSemaglutide14$27,430
OzempicSemaglutide14$27,386
MyrbetriqMirabegron24$19,099
EliquisApixaban13$13,625
Rosuvastatin Calcium86$2,155
Wixela InhubFluticasone Propion/Salmeterol13$2,067
Gabapentin71$1,607
Levothyroxine Sodium137$1,572
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,434
Estradiol21$1,424
Atorvastatin Calcium137$1,394
Fluticasone Propionate64$1,292
Omeprazole70$1,263
Azelastine Hcl25$1,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$113$54,81728 claims
Boehringer IngelheimJardiance$373$42,38831 claims
Astellas Pharma US IncMyrbetriq$51$19,09924 claims
PfizerEliquis$204$13,62513 claims
AbbVieSynthroid$234$1,02323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Coronado

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →